Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 4, 2019--
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial results after market close on Thursday, November 7, 2019.
Management will host a conference call at 4:30 p.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live via the Internet and will be available on the “Investors & Media” section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company’s website.
The call can also be accessed by dialing (855) 453-3834 or (484) 756-4306 (international) and referencing conference ID 1475058 prior to the start of the call. After the conference call, a replay will be available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and refer to conference ID 1475058.
About Dicerna™ Pharmaceuticals, Inc.
Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The Company’s proprietary GalXC™ technology is being applied to develop potent, selective, and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005122/en/
Stern Investor Relations, Inc.
Lauren Stival, 212-362-1200
Alex Van Rees, 973-442-1555 ext. 111
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA GENETICS CLINICAL TRIALS
SOURCE: Dicerna™ Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 11/04/2019 07:30 AM/DISC: 11/04/2019 07:31 AM